Interleukin 28B Gene Polymorphisms and Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Ela Akay    Mauli Patel    Tim Conibear    Turren Chaggar    Tanzina Haque
Department of Virology, Royal Free Hospital, London, UK

Abstract

Objectives: Single-nucleotide polymorphisms (SNPs) near the interleukin (IL) 28B gene encoding a type III interferon (IFN-λ) are the most important genetic predictors of treatment response to hepatitis C virus (HCV). This retrospective study was undertaken to determine any association between IL28B SNPs and the development of viremia in Epstein-Barr virus (EBV)-driven acute infectious mononucleosis (IM) and post-transplant lymphoproliferative disease (PTLD).

Methods: Genomic DNA extracted from plasma from 45 EBV seropositive controls and 46 acute IM, 23 non-PTLD (transplant) and 21 PTLD patients was tested by PCR for 2 SNPs within IL28B. EBV DNA levels were tested in IM and PTLD samples by a real-time quantitative PCR.

Results: No significant differences were seen in SNP frequencies at rs12979860 and rs8099917 in IM and PTLD patients compared to EBV seropositive controls and transplant patients. EBV DNA levels were lower in IM and PTLD patients with CC (a favourable genotype in HCV) compared to non-CC genotypes (p = 0.055). Acute IM patients with CC had significantly lower levels of EBV DNA in plasma compared to those with non-CC genotypes (p = 0.011).

Conclusions: Genotype CC may influence anti-viral responses of IFN-λ, thereby allowing better control of EBV viremia during lymphoproliferation, particularly in IM.

Keywords
IL28B gene polymorphisms · Epstein-Barr virus · Acute infectious mononucleosis · Posttransplant lymphoproliferative disease · Viral load
ymptomatic in the majority of people but can present as an acute self-limiting lymphoproliferative disease known as infectious mononucleosis (IM). Immunocompromised individuals such as transplant recipients can develop EBV-driven post-transplant lymphoproliferative disease (PTLD). It is not clear why some individuals develop symptomatic diseases with EBV and others do not. Studies have identified certain polymorphisms in human leukocyte antigen A loci and in tumour necrosis factor (TNF) α genes that may be associated with the development of IM and PTLD, respectively [6, 7]. It is possible that IL28B polymorphisms can affect the outcome of chronic viral infections such as herpes viruses. This retrospective study was undertaken to determine if the inheritance of 2 of the most investigated IL28B polymorphisms (rs12979860 and rs8099917) was associated with the development of EBV diseases, such as IM and/or PTLD, and with the control of EBV viraemia.

Plasma samples from 135 individuals were retrospectively analysed, including 45 EBV seropositive healthy individuals with serological evidence of past EBV infection (healthy controls), 46 patients with clinically diagnosed and serologically confirmed (IgM and IgG antibodies to EBV viral capsid antigen positive and IgG to EBV nuclear antigen negative) acute IM, 23 adult heart and/or lung transplant recipients without PTLD (transplant patients) and 21 patients who developed biopsy-proven EBV-positive PTLD. All of these patients were enrolled into a previous clinical trial which had ethical approval from the appropriate ethics committee. Acute IM and PTLD samples were collected at the time of clinical, serological and biopsy-confirmed diagnosis. All samples were anonymised at source and given unique identifying numbers, and aliquots of stored plasma samples were used. Genomic DNA was extracted from plasma samples using the QIAsymphony Mini DNA blood extraction kit. Real-time PCR was performed for 2 SNPs within the IL28B locus (C or T for the rs12979860 site and G or T for the rs8099917 site) using a TaqMan allelic discrimination assay, as previously described [8]. EBV DNA was quantitated by a real-time quantitative PCR, as previously described [9]. Statistical analyses between allele frequencies were performed using Fisher’s exact test with GraphPad Prism 5. For rs12979860, the CC genotype was compared with non-CC genotypes (CT and TT). For rs8099917, GG and GT (unfavourable) were compared with the TT genotype.

There were a total of 64 males and 71 females in the study, with ages ranging from 1 to 67 years. Average ages for healthy controls and acute IM, transplant and PTLD patients were 22, 21, 40 and 32 years, respectively. Of the 135 patients tested, 66 (49%) had CC, 48 (35.5%) had CT and 21 (15.5%) had TT genotypes at the rs12979860 site. For the rs8099917 site, the overall genotype frequencies were 6% for GG, 32% for GT and 62% for TT. There were no statistically significant differences in the frequency of any genotype for either rs12979860 or rs8099917 in IM and PTLD patients compared to healthy controls and transplant patients, respectively (fig. 1). The percentage of CC at rs12979860 (favourable genotype) was lower (43%; 9/21) in PTLD patients compared to transplant patients (57%; 13/23), but this was not statistically signifi-
cant (p = 0.2). There was no correlation between the histological types of PTLD and particular SNPs.

EBV DNA levels in plasma were tested and compared in acute IM and PTLD patients based on their IL28B SNPs. Overall, 51 out of 67 (76%) acute IM and PTLD samples tested had detectable EBV DNA (median 6,493 copies/ml, range 103–4,997,550 copies/ml), although no particular genotype was associated with the likelihood of developing EBV DNAemia. However, IM and PTLD patients with the CC (favourable) genotype at rs12979860 had lower levels of EBV DNA compared to those with non-CC (CT and TT) genotypes (borderline statistical significance, p = 0.055). When analysed separately, 34 of 46 IM samples (74%) had detectable EBV DNA (median 9,356 copies/ml, range 213–218,654 copies/ml). Patients with acute IM with the favourable genotype CC at rs12979860 had significantly lower levels of EBV DNA in blood compared to those with CT and TT genotypes (p = 0.011). This difference became statistically significant in patients with primary EBV infection and acute IM, as those with the CC genotype within the IM cohort had lower EBV DNA levels compared to those with CT/TT (p = 0.011).

CC has been shown to be the most favourable genotype to predict the outcome of natural and IFN-α-treated HCV infection. It is possible that the CC SNP near the IL28B gene is helpful in controlling EBV replication during acute infection via IFN-λ pathways. Several studies have implicated polymorphisms within cytokine genes, such as IL-10 and its promoter genes, in the risk of developing symptomatic primary EBV infection and its control [11, 12]. Our findings are based on EBV viral load testing on a single sample taken from patients at the time of diagnosis of acute IM and PTLD. It will be interesting to follow EBV levels in sequential samples to establish the further effect of IL28B genotypes in controlling viral replication. We recently showed that the soluble form of CD30, a member of the TNF receptor superfamily, was significantly increased in IM and EBV lymphoproliferative diseases [9]. An association between variant alleles within the TNF-α promoter and TNF receptor promoter regions with the development of PTLD has been shown, indicating that variations within TNF-α loci can be predictive risk factors for PTLD development [7, 13]. However, several studies reported no association between IFN-γ genotype and the development of EBV-positive PTLD in solid organ transplant patients [13, 14]. Therefore, our findings in IM and PTLD cohorts of a lack of significant differences in polymorphisms of the IL28B gene, which encodes IFN-λ, may not be surprising. Our sample sizes were too small to draw any conclusion. A larger cohort of patients is needed to determine whether IL28B gene polymorphisms can be predictive markers for the development of EBV-associated lymphoproliferative diseases.
References


